*Adverse gastrointestinal drug reactions with bisphosphonates include: irritation of the esophagus, difficulty swallowing, pain on swallowing, and heartburn. Patients with pre-existing upper gastrointestinal disorders, such as esophageal stricture, achalasia, or poorly controlled gastroesophageal reflux disease, should preferably not be treated with oral bisphosphonates.2
†Abdominal discomfort and constipation have been reported in patients with osteoporosis receiving Prolia®.9
DXA: dual x-ray absorptiometry.
- Kanis JA, et al. Osteoporos Int. 2001;12:989–95.
- Rizzoli R, et al. Osteoporos Int. 2014;25:2507–29.
- Fosavance® (alendronate) Summary of Product Characteristics.
- Cummings SR, et al. N Engl J Med. 2009;361:756–65.
- Bone HG, et al. Lancet Diabetes Endocrinol. 2017;5:513–23.
- Freemantle N, et al. Osteoporos Int. 2012;23:317–26.
- Palacios S, et al. J Clin Endocrinol Metab. 2015;100:E487–92.
- Kendler DL, et al. Osteoporos Int. 2011;22:1725–35.
- Prolia® (denosumab) Summary of Product Characteristics. Amgen. Last revised February 2020.